Investors Purchase High Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of unusually large options trading on Thursday. Investors purchased 4,052 call options on the stock. This represents an increase of 103% compared to the average volume of 1,999 call options.

Institutional Investors Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Analyst Ratings Changes

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd.

Reviva Pharmaceuticals Trading Up 11.0 %

Shares of Reviva Pharmaceuticals stock opened at $2.01 on Friday. The stock has a market capitalization of $67.22 million, a price-to-earnings ratio of -1.81 and a beta of -0.02. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $5.67. The business’s 50 day simple moving average is $1.46 and its 200-day simple moving average is $1.27.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.